Keratinocyte–Immune Cell Interactions in Chronic Dermatoses

Abstract

Chronic dermatoses such as psoriasis, atopic dermatitis, and lichen planus are characterized by complex interactions between keratinocytes and immune cells, which drive disease initiation, progression, and chronicity. Recent advances in immunodermatology have elucidated the bidirectional crosstalk between epidermal keratinocytes and a diverse array of immune cells, including T lymphocytes, dendritic cells, and innate lymphoid cells. These interactions underpin the inflammatory milieu and aberrant barrier function observed in chronic skin diseases. The present review integrates recent scientific evidence and clinical data to provide an up-to-date synthesis on the mechanisms, clinical implications, and therapeutic opportunities presented by keratinocyte–immune cell interactions in chronic dermatoses.

Introduction

Keratinocytes, the predominant cell type in the epidermis, play a central role not only as structural components of the skin barrier but also as active participants in cutaneous immune responses. In chronic dermatoses, dysregulation of keratinocyte–immune cell communication is fundamental to disease pathogenesis. A growing body of research underscores the significance of this cellular crosstalk in orchestrating inflammatory cascades, perpetuating skin barrier dysfunction, and shaping therapeutic responses. Understanding these multifaceted interactions is crucial for clinicians and researchers seeking to develop targeted therapies and improve clinical outcomes in patients with chronic skin diseases.

Epidemiology / Disease Burden

Chronic dermatoses, including psoriasis, atopic dermatitis, and chronic eczema, are among the most prevalent non-infectious skin disorders worldwide. Psoriasis affects approximately 2–3% of the global population, while atopic dermatitis impacts up to 20% of children and 3% of adults in industrialized countries. These diseases significantly impair quality of life, are associated with substantial healthcare costs, and often co-occur with systemic comorbidities such as cardiovascular disease, metabolic syndrome, and psychological disorders. The chronicity and recurrence of these dermatoses present ongoing challenges in both primary care and specialist settings.

Pathophysiology

The pathogenesis of chronic dermatoses is driven by a vicious cycle of keratinocyte–immune cell interactions. Keratinocytes respond to environmental insults by releasing cytokines (e.g., IL-1, IL-33, TSLP) and chemokines that recruit and activate immune cells, notably dendritic cells, T cells, and innate lymphoid cells. In psoriasis, for example, keratinocytes produce antimicrobial peptides and pro-inflammatory cytokines in response to IL-17 and IL-22 signaling, perpetuating epidermal hyperplasia and immune activation. In atopic dermatitis, barrier dysfunction leads to increased exposure to allergens and microbes, which drives type 2 helper T cell (Th2) skewed inflammation and further impairs keratinocyte function. The dynamic interplay between these cells sustains chronic inflammation and impedes resolution.

Risk Factors

Genetic susceptibility, environmental triggers, and epigenetic modifications collectively influence the risk for chronic dermatoses. Mutations in genes encoding structural proteins (e.g., filaggrin) or cytokine receptors (e.g., IL-23R) can alter keratinocyte function and immune responsiveness. Environmental factors such as mechanical injury (Koebner phenomenon), infections, allergens, and psychological stress modulate keratinocyte–immune cell signaling pathways. Additionally, comorbidities like obesity and metabolic syndrome are associated with chronic low-grade inflammation, further exacerbating disease risk and severity.

Clinical Features

Chronic dermatoses manifest with a spectrum of cutaneous and systemic symptoms reflective of underlying keratinocyte–immune cell dysregulation. Psoriasis typically presents as well-demarcated erythematous plaques with silvery scale, while atopic dermatitis is characterized by pruritic, lichenified, and eczematous lesions. The chronicity of inflammation can lead to skin thickening, fissuring, secondary infections, and pigmentary changes. Systemic symptoms such as fatigue, joint pain (in psoriatic arthritis), and sleep disturbances are not uncommon, highlighting the need for holistic patient assessment and management.

Diagnosis

Diagnosis of chronic dermatoses relies on a combination of clinical evaluation, histopathological examination, and emerging molecular biomarkers. Skin biopsy remains the gold standard for distinguishing between psoriasis, atopic dermatitis, and other inflammatory dermatoses. Immunohistochemical staining and gene expression profiling can provide insights into specific keratinocyte and immune cell signatures, guiding personalized therapeutic approaches. Recent advances in non-invasive imaging (e.g., reflectance confocal microscopy) and serum biomarkers hold promise for improved disease monitoring and early detection of disease flares.

Treatment & Management

Therapeutic strategies for chronic dermatoses are increasingly tailored to target key keratinocyte–immune cell pathways. Topical corticosteroids, calcineurin inhibitors, and phototherapy remain mainstays for mild disease. Systemic agents such as methotrexate, cyclosporine, and retinoids are reserved for moderate-to-severe cases. Biologic therapies targeting TNF-α, IL-17, IL-23, and IL-4/IL-13 pathways have transformed management, offering rapid and sustained disease control with favorable safety profiles. Effective management requires a multidisciplinary approach, addressing skin care, comorbidities, psychological support, and patient education.

Recent Advances / Emerging Therapies

Recent years have witnessed the advent of novel small molecules, biologics, and topical agents that specifically modulate keratinocyte–immune cell interactions. Janus kinase (JAK) inhibitors and phosphodiesterase-4 (PDE4) inhibitors represent oral options with proven efficacy in both psoriasis and atopic dermatitis. Ongoing research is exploring the therapeutic potential of targeting keratinocyte-derived cytokines (e.g., IL-36, IL-33), as well as therapies that restore barrier integrity and modulate the skin microbiome. Personalized medicine approaches, leveraging genetic and molecular profiling, are poised to revolutionize the management of chronic dermatoses in the near future.

Guideline Recommendations

Current international and national guidelines emphasize a stepwise approach to the management of chronic dermatoses, incorporating disease severity, patient preferences, and comorbidity profiles. Early initiation of targeted therapies is recommended for patients with moderate-to-severe disease or those with significant impact on quality of life. Regular monitoring of treatment efficacy, adverse events, and comorbidities is essential. Multidisciplinary collaboration between dermatologists, primary care physicians, and allied health professionals is advocated to optimize patient outcomes and address the complex needs of individuals with chronic dermatoses.

Conclusion

Keratinocyte–immune cell interactions are central to the pathogenesis and clinical expression of chronic dermatoses. Advances in our understanding of these mechanisms have paved the way for innovative therapies that target specific molecular pathways, resulting in improved disease control and patient quality of life. Ongoing research into the molecular underpinnings of keratinocyte–immune cell crosstalk holds promise for the development of precision medicine strategies that will further enhance the management of chronic skin diseases in clinical practice.